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Allogeneic hematopoeitic progenitor cell transplantation (HPCT) is a curative therapy for pediatric patients
with both malignant and nonmalignant diseases. Single or multiple benign exostoses or osteochondromas
have been reported after total body irradiation (TBI), as well as after focal irradiation. Patients exposed to TBI
at a young age are at highest risk of developing exostoses. The objective of this institutional review board
eapproved study was to look at potential factors, besides radiation, that may play a role in development of
exostoses. All patients who underwent allogeneic and autologous HPCT at a single institution between March
1992 and December 2003 and who developed an exostosis identiﬁed by clinical ﬁndings or as an incidental
ﬁnding on a radiologic study were included. A case-control design matched patients with controls who had
the same stem cell source.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION SUBJECTS AND METHODS
Hematopoietic progenitor cell transplantation (HPCT) is
a curative therapy for pediatric patients with both malignant
and nonmalignant diseases. It is our goal to not only cure, but
to also decrease the amount and severity of long-term
sequelae after HPCT for these pediatric patients. Nonmalig-
nant late effects have begun to be well documented in this
patient population [1]. The development of exostoses, or
benign osteochondromas, is one such late effect.
Exostoses are cartilage-capped growths of bone that
develop during physeal growth. They result from the sepa-
ration of a part of epiphyseal growth plate cartilage, which
then pushes through the periosteal cuff that normally
surrounds the growth plate [2]. Exostoses are typically
considered to be developmental lesions and not neoplastic in
origin.
Hereditary multiple exostoses (HME) is an autosomal
dominant trait characterized by slightly stunted growth of
long bones and multiple exostoses [3]. HME can occur as an
isolated lesion or as a part of a microdeletion syndrome, such
as Langer-Giedion or Defect 11, which implicates a deletion of
the EXT gene [4]. HME occurs at an incidence of 1 in 50,000
live births.
We have noted exostoses in our HPCT population anec-
dotally over the past 10 years. These have been seen mostly
after allogeneic HPCT, but also, on occasion, after autologous
HPCT. Because there is a paucity of literature in the pediatric
HPCT setting regarding the formation of exostoses, we
retrospectively reviewed our HPCT experience.dgments on page 1270.
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13.05.015All patients seen at Lurie Children’s Hospital Oncology and Hemato-
poietic Stem Cell Transplantation Survivor program, or by other providers in
the hematology-oncology-transplant group, who have undergone HPCT, and
who have had an exostosis conﬁrmed with radiology or as an incidental
ﬁnding on a radiologic study were included. The identiﬁed cases were
matched to controls without exostoses at the time of inclusion. Cases and
controls were matched by the following criteria: primary diagnosis
(malignancy [n¼ 23] versus nonmalignancy [n¼ 3]); HPCT type (autologous
[n¼ 2] or allogeneic [n¼ 24]); matched related donor (n¼ 15); mismatched
related donor (n ¼ 3); mismatched unrelated umbilical cord blood (n ¼ 5);
matched unrelated donor peripheral blood (n ¼ 1), age within 3 years but
limited to the same side of puberty; conditioning regimen; and stem cell
source. We attempted to match for gender but were not able to ﬁnd same
sex matches for all cases.
Treatment-related variables, such as HPCT conditioning regimen and
history of complications, were collected, as were ﬁndings from physical
exams and any studies performed during the course of clinical care.
Examples include location of exostosis, kidney function tests, calcium levels,
and imaging including x-rays and bone age. Data were collected from time
points including pre-HPCT, Day þ100, and most recent follow-up. Variables
were chosen to be comprehensive in evaluating major organ systems that
might contribute to exostosis development.
Both autologous and allogeneic patients were evaluated. All allogeneic
patients underwent HCT with traditional myeloablative conditioning regi-
mens containing total body irradiation (TBI). Patient ages ranged from
4 months to 9.4 years at time of transplantation.
Allogeneic HCT cell sources included matched related donor, mis-
matched related donor (sibling and other relative), matched unrelated
donor, and mismatched unrelated umbilical cord blood.
Unpaired, univariate comparisons were performed by Fischer exact
2-tailed analysis. Logistical regression modeling also performed to predict
groups at risk for development of exostoses.
RESULTS
Study Population
From March 1992 through December 2003, 445 patients
received HPCT (261 allogeneic and 184 autologous), and to
date, 27 of those patients have been diagnosed by clinical
and/or radiologic ﬁndings with exostoses. Twenty-four of the
27 exostosis cases were in the allogeneic setting; 3 of 27,
autologous. One of the 3 autologous cases was reported
verbally to us several years after HPCT and our institution
had no clinical or radiologic follow-up, so that patient is not
included in the data analysis. Anecdotally, that patient went
Table 1
Characteristics of Case and Control Group
Characteristic Exostosis
n ¼ 26
Control Group
n ¼ 26
Statistical
Signiﬁcance
Gender *matched Chi-square,
P ¼ .760; Fischer
exact, P ¼ 1.0
Male 19 (73%) 18 (69%)
Female 7 (27%) 8 (31%)
Age at HPCT, mean
(range), yr
3.9 (.3 to 9.4) 6.3 (.8 to 16.1) Paired, P ¼ .004
Race
Caucasian 17 14
Hispanic 8 8
African American 1 3
Asian/Indian 0 1
Diagnosis
Malignancy 23 24
Nonmalignancy 3 2
Allo HPCT 24 (92%) 24 (92%)
MRD 16 of 24 (67%) 10 of 24 (42%)
Mis-RD 2 of 24 (8%) 1 of 24 (4%)
MisU-UCB 5 of 24 (21%) 13 of 24 (54%)
MUD-PB 1 of 24 (4%) 0
Auto HPCT 2 2
TBI 23 of 24 (96%) 24 of 24 (100%)
Multiple exostoses
sites
15 of 26 (58%) na
HPCT indicates hematopoietic progenitor cell transplantation; MRD,
matched related donor; MisRD, mismatched related donor; MisU-UCB,
mismatched unrelated umbilical cord blood; MUD-PB, matched unrelated
donor-peripheral blood; TBI, total body irradiation.
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at the right distal tibia. He underwent amputation and
chemotherapy. He subsequently developed hepatocellular
carcinoma and underwent embolization but progressed after
approximately 3 months and succumbed to disease. We,
therefore, suspect that the patient had an underlying
susceptibility to malignancy that could also possibly explain
the unusual exostosis with malignant transformation.
Among the 24 (10.9%) patients with exostoses after allo-
geneic HCT, there were 17 males (71%) and all but 3 under-
went transplantation for malignancy (91%). All were treated
with allogeneic HPCT between .5 and 9.4 years of life. In the
exostosis-affected group 23 of 26 (88%) received TBI. TheTable 2
Risk Factors for Development of Exostoses
Variable Exostosis
n ¼ 26
C
n
AGvHD (n¼ allogeneic only) 9 of 24 (38%) 1
CGvHD (n¼ allogeneic only) 5 of 24 (21%) 7
Steroids 100 days 9 of 25 (36%) 1
Steroids >100 days 9 of 24 (38%) 9
Renal Insufﬁciency (bun/cr) 3 of 25 (12%) 2
Growth HRT 12 of 26 (46%) 8
Gonadal HRT 8 of 26 (31%) 7
Gonadal HRT (testosterone) 5 of 8 (63%) 3
Gonadal HRT (estrogen) 3 of 8 (38%) 4
Height 18 1
Weight
BMI
SMN 7 of 26 (27%) 4
Bone age ¼0 SD change
(n¼ # tested)
3 of 19 (16%) 7
Bone age > 1SD change 11 of 19 (58%) 4
Bone age > 2SD change 5 of 19 (26%) 2
AGvHD indicates acute graft-versus-host disease; CGvHD, chronic graft-versus-ho
Data are presented as n (%) unless otherwise indicated.matched control group had 25 of 26 (96%) with TBI-
containing regimens (McNemar P ¼ 1).
Both of the remaining autologous HPCT patients with
exostoses were males age 1 and 4.5 years, respectively, at
HPCT with malignancies, and both had intended tandem
HPCTs (1 underwent a double and 1 underwent a triple
tandem HPCT).
Additional demographic and treatment information can
be found in Table 1. Of note, patients were younger at HPCT
(3.9 versus 6.3 years, paired t-test P ¼ .004) and had longer
follow-up than controls (11.7 versus 8.8 years, P¼ .003). Of all
patients with exostosis, 58% presented with multiple sites,
usually not interfering with joint articulation or range of
motion. Most occurred at the extremities, although 5 of 26
(19%) cases were axial, such as ribs or scapulae.
The conditioning regimen for the majority of patients in
both the cases (23 of 26) and control group (25 of 26) con-
tained a TBI backbone of 12 Gy, which was delivered in eight
150 cGy fractions and two 150 cGy fractions per day for 4
days. Although TBI was used in almost all of the cases (88%),
alkylating agents were also a common thread with 16 of 26
(62%) in the exostosis group receiving cyclophosphamide
and etoposide with the TBI, whereas other variations
included TBI/cytosine arabinoside (n ¼ 2) and TBI/thiotepa/
cyclophosphamide (n ¼ 2).
The case group had a length of follow-up after HCT with
a mean of 11.7 years, whereas the control group had a mean
of 8.8 years (paired 2-tailed test, P ¼ .003).
Growth Hormone Replacement Exposure
Among the other potential risk factors examined (Table 2)
was growth hormone replacement therapy (GHRT), which
was used in both the affected and control group for short
stature. Twelve of 26 (46%) in the exostosis group received
GHRT, and 8 of 26 (31%) of the control group received GHRT.
Paired data analysis was not signiﬁcant for the use of GHRT
in either the exostosis cases or the control group (McNemar
P ¼ .344). Unpaired analysis was also not signiﬁcant (Fischer
exact P ¼ .393).
Graft-Versus-Host Disease
Only acute (A) graft-versus-host disease (GvHD) was
shown to be different between the groups for risk ofontrol Group
¼ 26
Paired P Values (Chi-square; Fisher Exact)
8 of 24 (75%) P ¼ .012; P ¼ .025
of 24 (29%) P ¼ .510; P ¼ .743
7 of 26 (65%) P ¼ .036; P ¼ .051
of 26 (35%) P ¼ .832; P ¼ 1.0
of 25 (8%) P ¼ .637; P ¼ 1.0
of 26 (31%) P ¼ .254; P ¼ .393
of 26 (27%) P ¼ .760; P ¼ 1.0
of 7 (43%)
of 7 (57%)
9
of 26 (15%) P ¼ .308; P ¼ .499
of 13 (54%)
of 13 (31%)
of 13 (15%)
st disease; HRT, hormone replacement therapy; SD, standard deviation.
Table 3
SMN Characteristics
þ TBI Focal radiation n (%) Age at ﬁrst HPCT Time HPCT to SMN Acute/Chronic GvHD
n (%) SMN in ﬁeld
n (% with focal)
Mean (range), yr Mean (range), yr %
Exostosis Cases with SMN (n¼6) 5 (83%) 5 (83%) 5.5 (.5 to 9.1) 11.3 (6.6 to 16.1) AGvHD 17%
2 of 5 (40%) CGvHD 50%
Exostosis Controls with SMN (n¼4) 3 (75%) 2 (50%) 4.9 (1.4 to 9.1) 9.0 (4.3 to 13.3) AGvHD 75%
1 of 2 (50%) CGvHD 25%
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controls experiencing AGvHD (paired P ¼ .022). In both
univariate, as well as multivariable modeling, the presence of
AGvHD correlates to a 75% less likelihood of having an
exostosis. Those without AGvHD have a 4.75 increased risk of
developing exostoses.
Correlating with the AGvHD was the use of steroids to
100 days, with 35% of cases versus 65% of controls (paired
P¼ .056) using steroids in the ﬁrst 100 days after HCT. Steroid
use after 100 days was not signiﬁcantly different between
the groups, nor was the development of chronic GvHD
(McNemar P ¼ .774).GROWTH
Analysis of most recent time points between cases and
controls for weight, height, and body mass index show both
groups are signiﬁcantly underweight and short, with nega-
tive Z-scores. The control group bodymass index Z-scorewas
not negative, but also not statistically signiﬁcant.
SECOND MALIGNANT NEOPLASMS
Second malignant neoplasms (SMN) were also seen in
this exostosis cohort. Five of 26 (19%) patients with exostosis
developed a SMN and 4 of those are alive to date. The SMN
diagnoses included 1 thyroid papillary carcinoma (patient
received 1200 cGy TBI), 1 osteogenic sarcoma of right distal
femur (patient received 1200 cGy TBI), 1 chondroblastic
osteosarcoma of left maxillary sinus (this patient also
received 3600 cGy cranial radiation, dose inclusive of 1200
cGy TBI), 1 Primitive NeuroEctodermal Tumor of the right
frontal lobe of the brain (patient received 1800 cGy CNS and
1600 cGy testicular irradiation, doses inclusive of 1200 cGy
TBI), and 1 gastrointestinal stromal tumor (patient received
1800 cGy Central Nervous System and 2500 cGy testicular,
doses inclusive of 1200 cGy TBI). Four of 5 patients had
multiple sites of exostoses, and the patient with osteogenic
sarcoma of the right distal femur had only 1 known site of
exostosis. There were no known sites of exostoses that
degenerated to osteosarcoma.
This compares with the development of SMN in 4 of 26
(15%) in the control group; of note, all of those developed
thyroid papillary carcinoma, and all had received TBI (1200
cGy) as a part of the myeloablative conditioning regimen.
There was no difference in time from HCT to SMN (or latest
follow-up) by Kaplan-Meier (cases, 14.9 years; control, 12.7
years; log rank P ¼ .35). Additional information about the
subjects with SMNs can be seen in Table 3.
DISCUSSION
Exostoses occur in the general population, although the
incidence may be underestimated, as many sporadic exos-
toses cause no symptoms and may go undetected [5]. Theincidence in the general population is reported at 1%, with an
increase to 10% in those where local irradiation has induced
an osseous change [4].
Patients with HMEwill often require surgical intervention
and/or resection related to a mass effect or neurovascular
impingement symptoms. It is important to note that those
with HME can eventually develop a chondrosarcoma in the
cartilage cap of the lesion [3]. Incidence of sarcomatous
degeneration to chondrosarcoma and osteosarcoma can
occur at an incidence almost equal to 2% in those with HME.
Although the incidence of malignant degeneration in
patients who have received radiation is not well understood,
there certainly are isolated reports of the development of
these malignancies [4].
Exostoses have been reported after TBI, as well as after
focal irradiation [3]. A higher incidence of exostoses in
pediatric patients after HCT has been seen in those who have
received TBI under the age of 5 years, along with multiple
sites of exostoses [2]. The cumulative dose of 12 gray of TBI
appears to be sufﬁcient to cause multiple sites of exostoses in
children [6].
We have used a case-control approach to attempt to
identify other risk factors for exostosis development besides
TBI in HCT survivors.
Because multiple studies implicate TBI as a risk factor for
the development of exostoses, especially in patients treated
at a young age, we assumed TBI to be a risk factor and used
a case-control design to attempt to identify other possible
risk factors that distinguish which patients receiving TBI
might be at highest risk of developing exostoses.
An interim analysis of data from this study had sug-
gested that GHRT was more common in exostosis cases
than controls; however, this difference was not statistically
signiﬁcant at the time of follow-up cutoff for this study.
GHRT has caused concern of the potential to proliferate
both normal as well as malignant cells. Several studies have
been performed to discern whether there is risk in children
with prior cancer history and then treated with growth
hormone to develop a recurrent or new malignancy [7]. A
study speciﬁc to childhood cancer survivors, utilizing
Childhood Cancer Survivor Study data, showed that there is
an increased risk for the development of SMN in those
survivors who were treated with growth hormone
compared to those without GHRT. However, this risk did
decrease as length of follow-up increased. Survivors who
had received GHRT had a rate ratio of 2.15 (95% conﬁdence
interval, P ¼ .002) to develop an SMN, as compared with
those survivors not treated with GHRT [8].
The trend that more cases (46%) than controls (31%) were
treated with GHRT still exists, but is possibly confounded by
the longer follow-up among cases. The time factor is an
important one as well, and a potential limitation of our
ﬁndings, with longer time at risk possibly being one of the
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cases. Length of follow-up was the only signiﬁcant variable
(P ¼ .021).
The length of follow-up after HPCT in both the case and
control group was signiﬁcant with a paired analysis
(P ¼ .003), with the cases having a longer follow-up at 11
years versus the controls at 8 years. This could mean that the
longer patients survive will reveal more diagnosis of exos-
toses over time.
Our data show that for each additional year of follow-up,
there is an odds ratio of 1.274 (P ¼.037) or a 27% increased
likelihood per year to develop an exostosis. Interestingly, at
the time of this writing, 3 more patients were diagnosed
with exostoses conﬁrmed by medical imaging, (2 allogeneic,
1 autologous), 1 of whom was in the control group.
The time to clinical recognition of exostoses is not
necessarily biologically relevant as it is only a determination
after a ﬁnding upon physical exam, after a clinical sign or
symptom, or coincidentally as a radiological ﬁnding. The
actual biologic onset remains unknown.
It appears that younger age at exposure to 12 Gy of TBI
and/or HPCT increases the risk of development of exostoses
9. Further longitudinal follow-up is necessary to discern
other variables that may play a role in the development of
exostoses. For occurrence of exostoses, our study showed
only acute GVHD to be different between the groups, and
the likelihood of SMN was similar for cases and controls. Of
the 10 SMNs, 50% were thyroid carcinomas, which are
common after low-dose radiation exposure to the thyroid.
Of note, 43% of the other solid SMNs among this group
occurred in the ﬁeld of focal radiation for the primary
tumor, highlighting the importance of high-dose focal
radiation as a SMN risk.
Analysis into the incidence of exostosis in children
undergoing HPCT with reduced intensity, and or non-TBI or
lower TBI containing conditioning regimens may help todetermine more of the treatment-related variables that can
cause these lesions. Prospective study of those with known
exostoses will aid clinicians in the continued evaluation and
management of these children.ACKNOWLEDGMENTS
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